TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors (NASDAQ:TGTX)
· seekingalpha.com
TG Therapeutics is a prime takeover target, fueled by Briumvi's growth and recent subcutaneous formulation de-risking. Learn why TGTX stock is a buy.
I publish my best ideas and top coverage on the Growth Stock Forum. If you're interested in finding great growth stocks, with a focus on biotech, consider signi...